Sanofi SA (MIL:1SAN) Share Price

Company Profile

Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from cardiometabolic will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs, with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRA
T: +33 153774000
E: [email protected]
https://www.sanofi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878

Recommended

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Malik Ahmed Khan, CFA | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,997.60	17.80	-0.20%
CAC 40	7,861.96	4.60	0.06%
DAX 40	24,262.22	44.85	0.19%
Dow JONES (US)	44,461.28	171.71	-0.38%
FTSE 100	9,136.94	0.62	0.01%
HKSE	24,834.54	342.39	-1.36%
NASDAQ	21,129.67	31.38	0.15%
Nikkei 225	41,020.91	366.21	0.90%
NZX 50 Index	12,857.52	1.55	0.01%
S&P 500	6,362.90	7.96	-0.12%
S&P/ASX 200	8,740.80	15.60	-0.18%
SSE Composite Index	3,582.96	32.76	-0.91%